Intravenous treatment with Mitoxantrone in active secondary progressive multiple sclerosis: effects on adaptive immune system.
- Conditions
- Secondary progressive multiple sclerosis
- Registration Number
- NL-OMON26011
- Lead Sponsor
- R. HuppertsOrbis Medical CenterDepartment of NeurologyPostbus 55006130 MB Sittard-Geleen
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
1. Secondary progressive MS patients who are treated with mitoxantrone according to normal neurological practice;
2. Age 18-65;
Exclusion Criteria
1. Relapsing remitting multiple sclerosis;
2. Treatment with intravenous corticosteroids in the last 30 days;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. T cell compartment;<br /><br>2. B-cell compartment;<br /><br>3. Vitamin D.<br>
- Secondary Outcome Measures
Name Time Method Expanded disability status scale score.